INTRODUCTION: Supratentorial ependymomas are rare neoplasms accounting for just ten to 15 new cases in the UK per year. This article discusses the surgical management of these tumours. MATERIALS AND METHODS: We present our experience over the past 12 years looking, in particular, at the location, histological grading, postoperative complications, survival and progression-free survival. A literature review of publications discussing the surgical management of ependymoma over the past 10 years is then presented. RESULTS: The data shows that complete surgical resection confers a significant survival advantage. There appears to be conflicting data with respect to prognosis when comparing supratentorial to infratentorial ependymoma. CONCLUSION: The authors suggest complete excision and advocate, where appropriate, the use of pre and intra-operative functional mapping and second-look surgery. The trade off neurological deficit in the pursuit of complete surgical excision in some instances should be considered.
INTRODUCTION:Supratentorial ependymomas are rare neoplasms accounting for just ten to 15 new cases in the UK per year. This article discusses the surgical management of these tumours. MATERIALS AND METHODS: We present our experience over the past 12 years looking, in particular, at the location, histological grading, postoperative complications, survival and progression-free survival. A literature review of publications discussing the surgical management of ependymoma over the past 10 years is then presented. RESULTS: The data shows that complete surgical resection confers a significant survival advantage. There appears to be conflicting data with respect to prognosis when comparing supratentorial to infratentorial ependymoma. CONCLUSION: The authors suggest complete excision and advocate, where appropriate, the use of pre and intra-operative functional mapping and second-look surgery. The trade off neurological deficit in the pursuit of complete surgical excision in some instances should be considered.
Authors: J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Arnold C Paulino; B-Chen Wen; John M Buatti; David H Hussey; Weining K Zhen; Nina A Mayr; Arnold H Menezes Journal: Am J Clin Oncol Date: 2002-04 Impact factor: 2.339
Authors: J Guyotat; F Signorelli; S Desme; D Frappaz; G Madarassy; M Fevre Montange; A Jouvet; Ph Bret Journal: J Neurooncol Date: 2002-12 Impact factor: 4.130
Authors: Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin Journal: Lancet Oncol Date: 2007-08 Impact factor: 41.316